Clinical trials: Acute Respiratory Infections
Common Cold, Acute Respiratory Infection
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infection.
- Conditions
- Common Cold, Acute Respiratory Infection, Influenza, Human
- Trial name
- NCT05273619
- Testing
- XC8, film-coated tablets, 10 mg
- Where
- 6 sites in Russia
- Volunteers
- 250 people
- Sponsor
- Valenta Pharm JSC
Covid19, SARS-CoV Infection
An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers
The BBV152 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04641481
- Testing
- BBV152
- Where
- India
- Volunteers
- 25,800 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Influenza, Human, Acute Respiratory Infection
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections
- Conditions
- Influenza, Human, Acute Respiratory Infection, Common Cold, Flu
- Trial name
- NCT03189537
- Testing
- Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
- Where
- 2 sites in Russia
- Volunteers
- 400 people
- Sponsor
- Valenta Pharm JSC
COVID 19 Disease, Mild to Moderate COVID 19 Disease
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease and low risk of disease progression (the "ACLR8-LR" study).
- Conditions
- COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2, Infectious Disease
- Trial name
- NCT05947812
- Testing
- Tafenoquine Oral Tablet
- Volunteers
- 148 people
- Sponsor
- 60P Australia Pty Ltd
Upper Resp Tract Infection
TEM-PCR™ Prospective Clinical Utility Study
This is a randomized, open-label, multi-center, prospective study to assess the clinical utility of the TEM-PCR Upper Respiratory Infection (URI) Panel in adult subjects age 65 and older presenting to the primary care clinic with…
- Trial name
- NCT04248361
- Testing
- TEM-PCR URI Panel, SOC/Empiric Diagnosis
- Where
- 4 sites in United States
- Volunteers
- 314 people
- Sponsor
- Diatherix Laboratories, LLC
COVID-19, SARS-CoV-2 Acute Respiratory Disease
A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.
- Trial name
- NCT05246137
- Testing
- COVID-19 Vaccine 40 ug/dose
- Where
- 18 sites in Italy, Spain
- Volunteers
- 2,646 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
COVID-19, Acute Respiratory Distress Syndrome
Tolerability and Efficacy of RJX in Patients With COVID-19
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
- Trial name
- RJX (NCT04708340)
- Testing
- Rejuveinix (RJX) Active Comparator
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Reven Pharmaceuticals, Inc.
Cough, Common Cold
PEACe: Ivy, Thyme and Cisti Extract (Phytus) Efficacy in Acute Cough
The purpose of this study is to investigate the efficacy of Phytus in Acute Cough
- Trial name
- PEACe (NCT02981147)
- Testing
- Phytus (Cisti, Thyme and Ivy Leaves)
- Where
- Pakistan
- Volunteers
- 210 people
- Sponsor
- PharmEvo Pvt Ltd
COVID-19, SARS-CoV2 Infection
COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche \& Abbott).
- Conditions
- COVID-19, SARS-CoV2 Infection, SARS (Disease)
- Trial name
- COVAG (NCT05074017)
- Testing
- 3 nasopharyngeal swab
- Where
- 2 sites in Germany
- Volunteers
- 2,222 people, healthy volunteers welcome
- Sponsor
- Synlab Holding Deutschland GmbH
COVID-19, Acute Kidney Injury
A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy
The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in subjects with an infectious etiology of Acute Kidney Injury (AKI).
- Conditions
- COVID-19, Acute Kidney Injury, Sepsis
- Trial name
- NCT04445220
- Testing
- SBI-101
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sentien Biotechnologies, Inc.
COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection
Study on Home Obstructive Respiratory Exacerbations
Strados Labs has developed the Strados™ Respiratory Care Platform, including the RESP™ Biosensor System, which encompasses a clinically validated wearable, non-invasive, Bluetooth-enabled device capable of remotely collecting…
- Conditions
- COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, COPD Exacerbation Acute, COPD
- Trial name
- SHORE (NCT06544928)
- Testing
- RESP™ Biosensor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Strados Labs, Inc.
Long Covid
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
This study is an interventional, randomized, multinational, multicenter, double-blind, phase 2 study with a follow-up period of 90 days.
- Trial name
- BLOC (NCT05911009)
- Where
- 16 sites in Austria, Finland and 3 more
- Volunteers
- 119 people
- Sponsor
- Berlin Cures GmbH
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute uncomplicated influenza.
- Trial name
- NCT02612922
- Testing
- Nitazoxanide
- Where
- 28 sites in United States, Australia and 1 more
- Volunteers
- 325 people
- Sponsor
- Romark Laboratories L.C.
COVID-19, Pneumonia, Viral
SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19
This protocol provides access to eculizumab treatment for participants with severe COVID-19.
- Conditions
- COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT04355494
- Testing
- eculizumab
- Where
- 12 sites in United States, France
- Sponsor
- Alexion Pharmaceuticals, Inc.
Covid19, Corona Virus Infection
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
- Conditions
- Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection
- Trial name
- NEUROSIVIR (NCT04480333)
- Testing
- Drug: NA-831 - 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Biomed Industries, Inc.
Respiratory Syncytial Virus
A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections
The purpose of the study is to assess viral kinetics and clinical symptoms kinetics in pediatric patients hospitalized with Respiratory Syncytial Virus (RSV) confirmed lower respiratory tract infection (LRTI).
- Trial name
- NCT02133092
- Testing
- No intervention
- Where
- 4 sites in Belgium
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC